UPR/MDACC: Partnership for Excellence in Cancer Research (1 of 2)

UPR/MDACC:癌症研究卓越合作伙伴关系(第 1 个,共 2 个)

基本信息

项目摘要

OVERALL PROJECT SUMMARY / ABSTRACT This competitive renewal of the Partnership for Excellence in Cancer Research (Partnership) between the University of Puerto Rico (UPR) and the University of Texas MD Anderson Cancer Center (MDACC) will: 1) solidify, strengthen, and expand the relationship between UPR and MDACC; and 2) leverage the breadth and strengths of an experienced and integrated Partnership in transition of the UPR Comprehensive Cancer Center (UPRCCC) towards a long-term overall goal: recognition of UPRCCC as an NCI-designated cancer center. To address some of the most profound cancer health disparities in Puerto Rico and Texas, the Partnership will establish an Infection-Driven Malignancies Program for Advancing Careers and Translational Sciences (IMPACT). This application represents a partnership in which both institutions profit from sharing distinct expertise to mutually benefit in implementation of integrated team science, outreach, education and career development initiatives. To facilitate UPRCCC's transition towards NCI-designation, the UPR PIs led the development of the specific aims with support of the MDACC PIs. The Specific Aims for the renewal are: 1) Develop a multidisciplinary research portfolio focused on health disparities derived from infection-driven malignancies; 2) Increase the number of Hispanic students pursuing careers in laboratory and population- based cancer research to produce a critical mass of clinicians, scientists, and physician-scientists, who specialize in cancer research, with emphasis on cancer health disparities in underrepresented minorities and underserved communities; 3) Strengthen sustainable collaborations among all the stakeholders to develop and promote key community outreach, education, and interventions aimed at reducing cancer rates and emphasizing vaccinations against malignancy linked infections, among Hispanic/Latino populations in PR, TX, and elsewhere; 4) Leverage strategic collaborations with NCI-designated cancer centers to augment the cancer research capacity of the UPR and the UPRCCC; and 5) Provide professional support and development tools through the a) Administration; b) Planning and Evaluation; and c) Shared Resources Cores designed to nurture and optimize the Partnership's research, education, and outreach agendas in support of the long-term goal of an NCI-designated Cancer Center. Key elements of this application to advance the Partnership include: 1) Multidisciplinary collaborative research projects focused on IMPACT that represent stages of the translational research continuum; 2) A comprehensive cancer-focused training and career development core; 3) The development of a dual MD/MPH degree to address specific cancers disproportionately affecting Hispanic populations; 4) Outreach efforts to build, educate, and advocate for broad HPV vaccination programs; and 5) a DATAOmics Core that builds infrastructure. This initiative will strengthen the overall cancer research enterprise in infection-driven malignancies in both PR and TX, and will support the implementation of UPRCCC's roadmap to submission of a Cancer Center Support Grant (P30) for NCI designation.
总体来说 项目摘要/摘要 这次癌症研究卓越伙伴关系(伙伴关系)的竞争性续签 波多黎各大学(UPR)和德克萨斯大学MD安德森癌症中心(MDACC)将:1) 巩固、加强和扩大普遍定期审议和普遍定期审议之间的关系;和2)利用 普遍定期审议综合癌症中心转型过程中经验丰富的综合伙伴关系的优势 (UPRCCC)迈向一个长期的总体目标:承认UPRCCC为NCI指定的癌症中心。至 解决波多黎各和德克萨斯州一些最严重的癌症健康差距,该伙伴关系将 建立感染驱动的恶性肿瘤项目,促进职业发展和翻译科学 (影响)。此应用程序代表了一种伙伴关系,在这种伙伴关系中,两个机构通过共享不同的 在实施综合团队科学、外联、教育和职业生涯方面互惠互利的专业知识 发展倡议。为了促进UPRCCC向NCI指定的过渡,UPR PIs领导了 在千年发展目标方案的支持下制定具体目标。更新的具体目标是:1) 开发多学科研究组合,重点关注由感染驱动的健康差距 恶性肿瘤;2)增加在实验室和人群中寻求职业生涯的西班牙裔学生的数量- 以癌症研究为基础,培养出一大批临床医生、科学家和内科科学家,他们 专门从事癌症研究,重点是代表不足的少数族裔和 服务不足的社区;3)加强所有利益攸关方之间的可持续合作,以制定和 促进关键的社区外联、教育和干预措施,旨在降低癌症发病率和 强调接种疫苗预防恶性肿瘤相关感染,在PR,德克萨斯州, 和其他地方;4)利用与NCI指定的癌症中心的战略合作来增强癌症 普遍定期审议和普遍定期审议中心的研究能力;以及5)提供专业支助和发展工具 通过a)行政管理;b)规划和评价;以及c)旨在培育 并优化伙伴关系的研究、教育和外联议程,以支持以下长期目标 一家由NCI指定的癌症中心。这项申请的关键要素包括:1) 多学科协作研究项目侧重于代表翻译阶段的影响 研究连续体;2)以癌症为重点的综合培训和职业发展核心;3) 开发双MD/MPH学位以应对对西班牙裔影响不成比例的特定癌症 4)建立、教育和倡导广泛的HPV疫苗接种计划的外联工作;以及5)a) 构建基础设施的DATAOmics核心。这一倡议将加强整个癌症研究企业 在PR和TX的感染驱动的恶性肿瘤方面,并将支持UPRCCC路线图的实施 提交癌症中心支持补助金(P30)以获得NCI称号。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHARON Hermes GIORDANO其他文献

SHARON Hermes GIORDANO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHARON Hermes GIORDANO', 18)}}的其他基金

Effects of biologic and targeted therapies for rheumatoid arthritis on cancer outcomes
类风湿关节炎的生物疗法和靶向疗法对癌症结果的影响
  • 批准号:
    10654754
  • 财政年份:
    2021
  • 资助金额:
    $ 105.41万
  • 项目类别:
Effects of biologic and targeted therapies for rheumatoid arthritis on cancer outcomes
类风湿关节炎的生物疗法和靶向疗法对癌症结果的影响
  • 批准号:
    10295119
  • 财政年份:
    2021
  • 资助金额:
    $ 105.41万
  • 项目类别:
Effects of biologic and targeted therapies for rheumatoid arthritis on cancer outcomes
类风湿关节炎的生物疗法和靶向疗法对癌症结果的影响
  • 批准号:
    10456286
  • 财政年份:
    2021
  • 资助金额:
    $ 105.41万
  • 项目类别:
Adherence Among Older Women with Breast Cancer
患有乳腺癌的老年女性的依从性
  • 批准号:
    7920692
  • 财政年份:
    2009
  • 资助金额:
    $ 105.41万
  • 项目类别:
Adherence Among Older Women with Breast Cancer
患有乳腺癌的老年女性的依从性
  • 批准号:
    6910857
  • 财政年份:
    2004
  • 资助金额:
    $ 105.41万
  • 项目类别:
Adherence Among Older Women with Breast Cancer
患有乳腺癌的老年女性的依从性
  • 批准号:
    7253371
  • 财政年份:
    2004
  • 资助金额:
    $ 105.41万
  • 项目类别:
Adherence Among Older Women with Breast Cancer
患有乳腺癌的老年女性的依从性
  • 批准号:
    7069093
  • 财政年份:
    2004
  • 资助金额:
    $ 105.41万
  • 项目类别:
Adherence Among Older Women with Breast Cancer
患有乳腺癌的老年女性的依从性
  • 批准号:
    6813996
  • 财政年份:
    2004
  • 资助金额:
    $ 105.41万
  • 项目类别:
Adherence Among Older Women with Breast Cancer
患有乳腺癌的老年女性的依从性
  • 批准号:
    7447892
  • 财政年份:
    2004
  • 资助金额:
    $ 105.41万
  • 项目类别:
UPR/MDACC: Partnership for Excellence in Cancer Research (2 of 2)
UPR/MDACC:癌症研究卓越合作伙伴关系(2 中的 2)
  • 批准号:
    10672313
  • 财政年份:
    2002
  • 资助金额:
    $ 105.41万
  • 项目类别:

相似海外基金

Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
  • 批准号:
    10760051
  • 财政年份:
    2023
  • 资助金额:
    $ 105.41万
  • 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
  • 批准号:
    2303692
  • 财政年份:
    2023
  • 资助金额:
    $ 105.41万
  • 项目类别:
    Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
  • 批准号:
    468168
  • 财政年份:
    2022
  • 资助金额:
    $ 105.41万
  • 项目类别:
    Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10427960
  • 财政年份:
    2022
  • 资助金额:
    $ 105.41万
  • 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
  • 批准号:
    10577074
  • 财政年份:
    2022
  • 资助金额:
    $ 105.41万
  • 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
  • 批准号:
    486588
  • 财政年份:
    2022
  • 资助金额:
    $ 105.41万
  • 项目类别:
    Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
  • 批准号:
    2760091
  • 财政年份:
    2022
  • 资助金额:
    $ 105.41万
  • 项目类别:
    Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10621188
  • 财政年份:
    2022
  • 资助金额:
    $ 105.41万
  • 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
  • 批准号:
    10891016
  • 财政年份:
    2021
  • 资助金额:
    $ 105.41万
  • 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
  • 批准号:
    10230365
  • 财政年份:
    2020
  • 资助金额:
    $ 105.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了